Antifungal Activity of Hydroalcoholic Extract of Chrysobalanus icaco Against Oral Clinical Isolates of Candida Species

Articles

Abstract
Pharmacognosy Research,2017,9,1,96-100.
Published:February 2017
Type:Original Article
Authors:
Author(s) affiliations:

João Paulo Bastos Silva1, Ana Regina Maués Noronha Peres1, Thiago Portal Paixão1, Andressa Santa Brígida Silva2, Ana Cristina Baetas1, Wagner Luiz Ramos Barbosa3, Marta Chagas Monteiro1, Marcieni Ataíde Andrade1

1Graduate Program in Pharmaceutical Sciences, Institute of Health Sciences, Federal University of Pará, Belém, Pará, BRAZIL.

2Pharmaceutical Innovation Graduate Program, Institute of Health Sciences, Federal University of Pará, Belém, Pará, BRAZIL.

3Graduate Program in Pharmaceutical Sciences, Institute of Health Sciences, Federal University of Pará; Pharmaceutical Innovation Graduate Program, Institute of Health Sciences, Federal University of Pará, Belém, Pará, BRAZIL.

Abstract:

Background: Chrysobalanus icaco is a medicinal plant commonly used to treat fungal infections in Brazilian Amazonian region. Objective: This work aimed to evaluate the antifungal activity of the hydroalcoholic extract of C. icaco (HECi) against oral clinical isolates of Candida spp. and to determine the pharmacognostic parameters of the herbal drug and the phytochemical characteristics of HECi. Materials and Methods: The pharmacognostic characterization was performed using pharmacopoeial techniques. Phytochemical screening, total flavonoid content, and high-performance liquid chromatography (HPLC) analysis were used to investigate the chemical composition of the HECi. A broth microdilution method was used to determine the antifungal activity of the extract against 11 oral clinical isolates of Candida spp. Results: Herbal drug presented parameters which were within the limits set forth in current Brazilian legislation. A high amount of flavonoid content (132,959.33 ± 12,598.23 μg quercetin equivalent/g of extract) was found in HECi. Flavonoids such as myricetin and rutin were detected in the extract by HPLC analyses. HECi showed antifungal activity against oral isolates of Candida albicans and Candida parapsilosis (minimum inhibitory concentrations [MIC] 3.12 and 6.25 mg/mL, respectively), and C. albicans American American Type Culture Collection (MIC <1.56 mg/mL). Conclusion: HECi was shown to possess antifungal activity against Candida species with clinical importance in the development of oral candidiasis, and these activities may be related to its chemical composition. The antifungal activity detected for C. icaco against Candida species with clinical importance in the development of oral candidiasis can be attributed to the presence of flavonoids in HECi, characterized by chromatographic and spectroscopic techniques.

PDF
Current View
Click here to download the PDF file.
Images

High‑performance liquid chromatography analysis of hydroalcoholic extract of Chrysobalanus icaco

Keywords